Delving into the Latest Updates on Xingji Biology (Suzhou) Co., Ltd with Synapse

Overview

Tags

Infectious Diseases

Other Diseases

Antibody

Fusion protein

Protein drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	7

Top 5 Drug Type	Count

Antibody	6
Protein drugs	1
Fusion protein	1
Monoclonal antibody	1

主要目的：评价XJ103注射液在健康受试者中单剂量给药的安全性和耐受性。次要目的：评价XJ103注射液在健康受试者中单剂量给药的药代动力学（PK）特征和免疫原性。探索性目的：评价XJ103注射液在健康受试者中单剂量给药的药效学（PD）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single dose of XJ103 injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics and immunogenicity of a single dose of XJ103 injection in healthy subjects. Exploratory objective: To evaluate the pharmacodynamic (PD) characteristics of a single dose of XJ103 injection in healthy subjects.

Start Date11 Oct 2023

Sponsor / Collaborator

Xingji Biology (Suzhou) Co., Ltd

CTR20232326

/ Active, not recruitingPhase 1

注射用XJ101在健康受试者中的安全性、耐受性、药代动力学及免疫原性特征：随机、双盲、安慰剂对照、单剂量递增的Ⅰ期临床研究

[Translation] Safety, tolerability, pharmacokinetics and immunogenicity of XJ101 for injection in healthy subjects: a randomized, double-blind, placebo-controlled, single-ascending dose phase I clinical study

主要目的：评价注射用XJ101在健康受试者中单剂量给药的安全性和耐受性。次要目的：评价注射用XJ101在健康受试者中单剂量给药的药代动力学（PK）特征和免疫原性。探索性目的：评价注射用XJ101在健康受试者中单剂量给药的药效动力学（PD）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single dose of XJ101 for injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics and immunogenicity of a single dose of XJ101 for injection in healthy subjects. Exploratory objective: To evaluate the pharmacodynamic (PD) characteristics of a single dose of XJ101 for injection in healthy subjects.

Start Date12 Sep 2023

Sponsor / Collaborator

Xingji Biology (Suzhou) Co., Ltd

NCT06026748

/ Active, not recruitingPhase 1

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ103 in Chinese Healthy Subjects

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.

Start Date12 Sep 2023

Sponsor / Collaborator

Xinyao Biology (Shanghai) Co., Ltd.

100 Clinical Results associated with Xingji Biology (Suzhou) Co., Ltd

Login to view more data

0 Patents (Medical) associated with Xingji Biology (Suzhou) Co., Ltd

Login to view more data

100 Deals associated with Xingji Biology (Suzhou) Co., Ltd

Login to view more data

100 Translational Medicine associated with Xingji Biology (Suzhou) Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

5

2

Preclinical

Phase 1 Clinical

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

XJ103	Pneumococcal Infections More	Phase 1
XJ-101	Staphylococcus Aureus Infections More	Phase 1
XJ-105	-	Preclinical
XJ104	Candidiasis More	Preclinical
XJ102	Pseudomonas Infections More	Discovery